Ryan Ungaro
Appearances
- DateMay 8, 2023Aconitate decarboxylase 1 (ACOD1; also known as IRG-1) is the ubiquitous source of the metabolite itaconate, which dampens inflammasome activation by preventing HIF1α production of IL-1β and prevents TNF production through NRF2 activation…
Presenter
Speakers
Icahn School of Medicine at Mount SinaiIcahn School of Medicine at Mount Sinai - DateMay 6, 2023Handout [https://ddw.digitellinc…
Presenters
Cedars-Sinai Medical CenterMayo Foundation for Medical Education and ResearchBrigham and Women's Hospital - DateMay 7, 2023BACKGROUND: Anti-granulocyte macrophage-colony stimulating factor autoantibodies (anti-GM-CSF) have been associated with development of Crohn’s disease (CD) and complications at time of diagnosis. There are limited data on anti-GM-CSF as a prognostic biomarker in CD…
Presenter
Speakers
Rhode Island Hospital/Hasbro Children's HospitalIcahn School of Medicine at Mount Sinai - DateMay 6, 2023BACKGROUND: Prevention of postoperative recurrence (POR) in Crohn’s disease (CD) after ileo-colonic (IC) resection is still a highly debated topic. Prophylactic immunosuppression after surgery is currently recommended in presence of at least one clinical risk factor (RF)…
Presenter
Speakers
NYU Langone HealthIcahn School of Medicine at Mount Sinai - DateMay 6, 2023
Speakers
Cedars-Sinai Medical CenterMayo Foundation for Medical Education and Research - DateMay 20, 2024Crohn’s disease (CD) is characterized by an aberrant microbiome composition – including a depletion of gut bacteria that produce short chain fatty acids (SCFA) – and by presence of anti-commensal systemic IgG…
Speakers
Icahn School of Medicine at Mount SinaiPresenter
Cedars-Sinai Medical Center Inflammatory Bowel Disease Center - DateMay 19, 2024BACKGROUND: The Montreal Classification (MC) captures the heterogeneity of Crohn's disease (CD). While the MC is an important tool for characterizing CD, its ascertainment for real-world studies requires manual chart review that is labor-intensive with limited scalability…
Presenter
Speakers
Icahn School of Medicine at Mount Sinai - DateMay 19, 2024Anti-granulocyte/macrophage-colony stimulating factor autoantibody (GM-CSF AuAB) has been identified before the onset of Crohn’s Disease (CD) and is associated with an increase in complicated disease. However, its connection to the gut microbiome, a key factor in CD progression, remains unclear…
Presenter
Speakers
Emory UniversityCincinnati Children’s Hospital Medical CenterIcahn School of Medicine at Mount Sinai - DateMay 19, 2024BACKGROUND: Crohn's disease (CD) can lead to progressive bowel damage and disability. Disability has been proposed by the SPIRIT-IOIBD consensus as an endpoint in disease-modification trials. Despite this, there is scarce data on disability at CD diagnosis…
Presenter
Speakers
Icahn School of Medicine at Mount Sinai - DateMay 18, 2024Approximately 20-30% of individuals with Crohn's disease (CD) experience a relatively mild disease course without progression. However, there is no widely accepted objective definition of mild CD. We aimed to identify endoscopic severity cut-offs that can be used to define mild non-progressive CD…
Presenter
Speakers
Icahn School of Medicine at Mount SinaiMassachusetts General Hospital - DateMay 18, 2024Approximately 20% of patients with Crohn’s disease (CD) have perianal fistulizing CD, which are most often complex perianal fistula (PAF). Studies have shown that 4-5% of patients with CD present with PAF without luminal disease, termed isolated perianal CD (iPCD)…
Presenter
Speakers
Icahn School of Medicine at Mount Sinai - DateMay 19, 2024Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) maintains mononuclear phagocytes (MNP) and supports intestinal immune homeostasis. Anti-GM-CSF autoantibodies (aGMAbs) are found in approx. 25% of all Crohn’s disease (CD) patients…
Speakers
Icahn School of Medicine at Mount SinaiPresenter